Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Maisel, AlanMueller, Christian
Nowak, Richard M
Peacock, W. Frank
Ponikowski, Piotr
Mockel, Martin
Hogan, Christopher
Wu, Alan H.B.
Richards, Mark
Clopton, Paul
Filippatos, Gerasimos S.
Di Somma, Salvatore
Anand, Inder
Ng, Leong L.
Daniels, Lori B.
Neath, Sean-Xavier
Christenson, Robert
Potocki, Mihael
McCord, James
Hartmann, Oliver
Morgenthaler, Nils G.
Anker, Stefan D.
Affiliation
VA San Diego Healthcare SystemSan Diego Veterans Affairs Medical Center
University Hospital Basel
Henry Ford Health System
The Cleveland Clinic
Charité Medical School
Virginia Commonwealth University
University of California
University of Otago
Athens University Hospital Attikon
University La Sapienza
B·R·A·H·M·S Aktiengesellschaft Biotechnology Centre
IRCCS San Raffaele, Rome
Issue Date
2011-08-30
Metadata
Show full item recordAbstract
The aim of this study was to determine the prognostic utility of midregion proadrenomedullin (MR-proADM) in all patients, cardiac and noncardiac, presenting with acute shortness of breath.Citation
Maisel, A. et al (2011) 'Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial' J. Am. Coll. Cardiol. 58 (10):1057-67Publisher
American College of CardiologyPubMed ID
21867843Additional Links
http://content.onlinejacc.org/article.aspx?articleid=1206940Type
ArticleLanguage
enISSN
1558-3597ae974a485f413a2113503eed53cd6c53
10.1016/j.jacc.2011.06.006